The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Sarepta Therapeutics ...

As of 2:40:46 PM EDT. Market Open. MOUNTAIN VIEW, Calif., March 19, 2025--Aeva® (Nasdaq: AEVA), a leader in next-generation sensing and perception systems, announced today that a global top 10 ...

In the current U.S. market landscape, stocks are showing signs of recovery following an encouraging Consumer Price Index report that has eased inflation concerns and sparked optimism for potential ...